Brief: SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro

SAB Biotherapeutics

16/12/2021 11:42

Dec 16 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS ANNOUNCES SAB-185 RETAINS
NEUTRALIZATION
AGAINST OMICRON SARS-COV-2 VARIANT IN VITRO
    * SAB BIOTHERAPEUTICS INC - FDA LABORATORY TESTING CONFIRMS
SAB-185 NEUTRALIZES OMICRON AND OTHER VARIANTS OF CONCERN WITH
IN VITRO PSEUDOVIRUS MODEL
    * SAB BIOTHERAPEUTICS INC - SAB'S TARGETED, HIGHLY POTENT
AND
FULLY-HUMAN POLYCLONAL ANTIBODIES CONTINUE TO SHOW BROAD
NEUTRALIZATION TO VIRAL VARIANTS
    * SAB BIOTHERAPEUTICS INC - SAB-185 CURRENTLY BEING
EVALUATED IN
NIH-SPONSORED PHASE 3 COVID TRIAL

Source text for Eikon:  ID:nGNXbM9pVK 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;;))